Be part of the knowledge.™

Oncology and Hematology

966

LikeLikedUnlike

136-150 of 285

Considering the Promise of New and Emerging Treatments for Hemophilia: The Need for ITI?
MinuteCE®
Considering the Promise of New and Emerging Treatments for Hemophilia: The Need for ITI?
- Stephanie Ambrose, DO
  Peer
- Jenny McDaniel, MD
  Peer
1.25 program credits
Considering the Promise of New and Emerging Treatments for Hemophilia: Managing Thrombotic Risks
MinuteCE®
Considering the Promise of New and Emerging Treatments for Hemophilia: Managing Thrombotic Risks
- Jenny McDaniel, MD
  Peer
- Stephanie Ambrose, DO
  Peer
1.25 program credits
Integrating New Therapies Into Healthcare
MinuteCE®
Integrating New Therapies Into Healthcare
- Stephanie Ambrose, DO
  Peer
- Jenny McDaniel, MD
  Peer
1.25 program credits
Multidisciplinary Team Collaboration in the New Era of Hemophilia Treatment
MinuteCE®
Multidisciplinary Team Collaboration in the New Era of Hemophilia Treatment
- Jenny McDaniel, MD
  Peer
- Stephanie Ambrose, DO
  Peer
1.25 program credits
Moving Forward–What Is on the Horizon? Personalized Therapies for Patients
MinuteCE®
Moving Forward–What Is on the Horizon? Personalized Therapies for Patients
- Jenny McDaniel, MD
  Peer
- Stephanie Ambrose, DO
  Peer
1.25 program credits
Enhancing Diagnosis, Treatment, and Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Novel Oral Therapeutics
CME/CE
Enhancing Diagnosis, Treatment, and Outcomes in Paroxysmal Nocturnal Hemoglobinuria with Novel Oral Therapeutics
- Carlos M. de Castro, MD
  Peer
0.50 credits
advertisement
Chairperson Perspective: Improving HR+/HER2- Breast Cancer Outcomes with TROP2 Antibody-Drug Conjugates
CME/CE
Chairperson Perspective: Improving HR+/HER2- Breast Cancer Outcomes with TROP2 Antibody-Drug Conjugates
- Aditya Bardia, MD, MPH
  Peer
0.25 credits
MinuteCE®
Chemotherapy Strategies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
- Eileen O’Reilly, MD
  Peer
- Efrat Dotan, MD
  Peer
0.25 credits 2 episodes
Chairperson Perspective: Core Concepts for Community-Based Practice: The Evolving Role of Bispecific Antibody Therapy in Relapsed or Refractory Follicular Lymphoma
CME/CE
Chairperson Perspective: Core Concepts for Community-Based Practice: The Evolving Role of Bispecific Antibody Therapy in Relapsed or Refractory Follicular Lymphoma
- Tycel Phillips, MD
  Peer
0.25 credits
MinuteCE®
Differentiating First-Line Treatment Selection: Combination Immunotherapy and Chemotherapy Regimens for Metastatic ESCC
- Harry Yoon, MD
  Peer
- Jaffer Ajani, MD
  Peer
0.75 credits 7 episodes
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
MinuteCE®
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
- Jaffer Ajani, MD
  Peer
0.75 program credits
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
MinuteCE®
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
- Harry Yoon, MD
  Peer
0.75 program credits
advertisement
Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
MinuteCE®
Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
- Harry Yoon, MD
  Peer
- Jaffer Ajani, MD
  Peer
0.75 program credits
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
MinuteCE®
Mutational Testing in mCRC: Methods and Data Driving Treatment Selection
- Fortunato Ciardiello, MD, PhD
  Peer
- Jenny Seligmann, MBChB, PhD
  Peer
1.00 program credits
From Guidelines to Practice: First-Line Treatment Choices in mCRC
MinuteCE®
From Guidelines to Practice: First-Line Treatment Choices in mCRC
- Fortunato Ciardiello, MD, PhD
  Peer
- Jenny Seligmann, MBChB, PhD
  Peer
1.00 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended